MALVERN, PA — Uniquity Bio appointed Jason Moore as senior vice president of regulatory and quality as the Blackstone-backed drug developer prepares for Phase II results that could determine whether its lead treatment advances into late-stage studies.
Moore will oversee regulatory and quality strategy as Uniquity awaits topline data this year from three Phase II trials of solrikitug in asthma, chronic obstructive pulmonary disease and eosinophilic esophagitis.
Solrikitug is a monoclonal antibody targeting thymic stromal lymphopoietin, or TSLP, a protein involved in inflammatory responses. Uniquity licensed the drug from Merck & Co.
“Adding Jason to our leadership team strengthens our position to move efficiently into late-stage development if the data supports it,” President and Chief Executive Officer Will Kane stated.
Moore most recently served as senior vice president of regulatory affairs and quality assurance at Nefro Avillion Clinical Development.
He previously held an executive role at Avillion Life Sciences, where he oversaw clinical development and marketing applications for AIRSUPRA in partnership with AstraZeneca. Nefro Health acquired Avillion in 2025.
Moore has also worked in regulatory, quality, clinical and program management roles at JEM Biopharma Consulting, Camargo Pharmaceutical Services, PLx Pharma and BioHouston.
His experience includes product development strategy, risk management, regulatory agency engagement, licensing reviews, portfolio planning and merger-and-acquisition diligence, according to Uniquity.
“I look forward to building on the company’s strong regulatory and quality foundation to ensure excellence as we scale,” Moore stated.
Alongside its Phase II program, Uniquity is evaluating bispecific and combination candidates that could pair solrikitug with other inflammatory targets. The company indicated those approaches could broaden the drug’s potential use or improve efficacy in selected indications.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.